Roivant Sciences LTD Form 4 insider transactions

QVT Financial LP, a 10% owner and director by deputization, reported selling 1.3 million common shares of Roivant Sciences Ltd. for approximately $26.3 million.

Roivant Sciences Director and 10% owner Vivek Ramaswamy sold over 1.8 million common shares for approximately $38 million in mid-November 2025.

Roivant Sciences' President and Immunovant CEO, Eric Venker, exercised stock options and subsequently sold 200,000 common shares for a significant gain under a pre-arranged 10b5-1 plan.

Roivant Sciences Ltd. Director Melissa B Epperly was awarded 1,056 common shares as part of the company's non-employee director compensation plan.

Roivant Sciences Director James C Momtazee received 789 common shares as an award and subsequently disposed of 158 shares for tax withholding purposes.

Roivant Sciences Director Ilan Oren reported the acquisition of 1,507 common shares as an award and the disposition of 281 shares for tax withholding purposes.

Roivant Sciences Ltd.'s President and Immunovant CEO, Eric Venker, executed a series of stock option exercises and subsequent sales of common shares in mid-October 2025, totaling 851,383 shares, under a pre-arranged 10b5-1 trading plan.

Roivant Sciences President and Immunovant CEO Eric Venker sold 125,667 common shares in October 2025, following option exercises, under a pre-arranged 10b5-1 trading plan.

Roivant Sciences Ltd. President and Immunovant CEO Eric Venker executed a series of planned option exercises and corresponding share sales totaling 665,159 shares over three days in October 2025.

Roivant Sciences CFO Richard Pulik disposed of 2,341 common shares to cover tax withholding obligations related to RSU vesting.

Roivant Sciences CFO Richard Pulik disposed of 2,129 common shares to cover tax withholding obligations related to vested restricted stock units.

Roivant Sciences Ltd. President and Immunovant CEO Eric Venker exercised stock options and subsequently sold a significant number of common shares in September 2025.

Roivant Sciences Ltd. CEO Matthew Gline acquired 3,315 common shares at a weighted average price of $15.07, increasing his beneficial ownership.

Roivant Sciences Director Keith Manchester was granted an annual equity award of restricted stock units and stock options, vesting in 2026.

Roivant Sciences Director Daniel Gold was granted restricted stock units and stock options, while also disposing of shares for tax obligations.

Roivant Sciences Ltd. director Meghan Fitzgerald was granted 14,524 restricted stock units and 33,726 stock options, while also disposing of 937 shares for tax obligations.

Roivant Sciences Ltd. director Ilan Oren was granted 14,524 restricted stock units and 33,726 stock options, while also disposing of 2,043 shares for tax purposes.

Roivant Sciences Director James C Momtazee was granted annual equity awards and disposed of shares for tax withholding purposes.

Roivant Sciences Director Melissa Epperly was granted new equity awards and sold shares to cover tax obligations related to prior vesting.

Roivant Sciences Director and 10% owner Vivek Ramaswamy sold over 1.7 million common shares in early September 2025.

Roivant Sciences CFO Richard Pulik disposed of 2,340 common shares to cover tax obligations from RSU vesting.

Roivant Sciences CFO Richard Pulik disposed of 1,235 common shares at $11.72 each to cover tax withholding on vested restricted stock units.

Roivant Sciences' President and Immunovant CEO, Eric Venker, reported the exercise of stock options and subsequent sale of common shares, alongside RSU tax withholding.

Roivant Sciences Ltd. President and Vant Chair Frank Torti was awarded 13,736,547 common shares through restricted stock units and performance-based units, vesting over time and contingent on share price hurdles.

Roivant Sciences' President and Immunovant CEO, Eric Venker, was granted 198,413 restricted stock units, increasing his beneficial ownership to over 1.6 million shares.

Roivant Sciences Ltd.'s CFO, Richard Pulik, reported the disposition of 1,919 common shares at $11.35 each to cover tax withholding obligations related to RSU vesting.

Roivant Sciences President and Immunovant CEO Eric Venker has filed a Form 4 indicating a future exercise of stock options and a simultaneous sale of common shares under a pre-arranged 10b5-1 plan.

Roivant Sciences Ltd. Director Ilan Oren reported an increase in his beneficial ownership of common shares through a compensation plan award, partially offset by shares withheld for tax obligations.

Roivant Sciences Director James C. Momtazee reported the acquisition of 1,201 common shares as an award and the disposition of 241 shares for tax withholding purposes, resulting in a net beneficial ownership of 96,670 shares.

Roivant Sciences Ltd. Director Melissa B. Epperly was awarded 1,609 common shares, effective July 17, 2025, as part of the company's Non-Employee Director Compensation Plan, increasing her total beneficial ownership to 42,985 shares.